Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2266 • ACR Convergence 2022
Platelet-selectin Prime Lupus Neutrophils to Produce Mitochondrial ROS and Participate in SLE Pathogenesis
Marc Scherlinger¹, Pierre Vacher², Vivien Guillotin³, Isabelle Douchet⁴, Christophe Richez⁵ and Patrick Blanco⁴, ¹BIDMC Harvard University, Boston, MA, ²INSERM U1218, Bordeaux, France, ³CHU de Bordeaux, Bordeaux, France, ⁴UMR-CNRS 5164 Immunoconcept, Bordeaux, France, ⁵CHRU Bordeaux, Bordeaux, France
Background/Purpose: In patients with active systemic lupus erythematosus (SLE), circulating platelets have an activated phenotype characterized by the expression of P-selectin (CD62P). We have shown…
Abstract Number: 0082 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on Healthcare Utilization Among Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients
Jean Park, W. Cliff Rutter, Will Cavers, Elisea Avalos-Reyes and Kjel Johnson, CVS Health, Lincoln, RI
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) are considered at risk for serious COVID infections due to their…
Abstract Number: 0221 • ACR Convergence 2022
Identifying and Addressing Gaps in Systemic Lupus Erythematosus Care via Multimodal Continuing Medical Education
Katie Robinson¹, Jillian Scavone¹, William Cioffi¹, Robert Esgro¹ and Leonard Calabrese², ¹Vindico Medical Education, Thorofare, NJ, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Given the recent advances in the management of patients systemic lupus erythematosus (SLE), rheumatology and primary care providers are challenged to administer the latest…
Abstract Number: 0334 • ACR Convergence 2022
Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records
Zara Izadi¹, Alfredo Aguirre², Christine Anastasiou², Julia Kay³, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵UCSF, San Rafael, CA
Background/Purpose: Real-world data could provide valuable information in the study of lupus nephritis (LN), if these cases could be reliably identified. A lack of ability…
Abstract Number: 0351 • ACR Convergence 2022
The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus: A Single-center Retrospective Study
Yasuhiro Hasegawa¹, Yoshiyuki Arinuma², Yu Matsueda¹, Kenji Oku³ and Kunihiro Yamaoka⁴, ¹Kitasato University School of Medicine, Sagamihara, Japan, ²Kitasato University, Kanagawa, Japan, ³Kitasato University, Chigasaki, Japan, ⁴Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Low disease activity (LDA) and remission in patients with systemic lupus erythematosus (SLE) can reduce organ damage accrual and improve prognosis. We investigated the…
Abstract Number: 0517 • ACR Convergence 2022
Cortical Surface Area Correlates with Cognitive Efficiency and Disease Measures in Childhood-Onset Systemic Lupus Erythematosus
Santiago Arciniegas¹, Sarah Mossad², Tala El Tal³, Victoria Lishak⁴, Stephanie Fevrier⁵, Ibrahim Mohamed⁶, Joanna Law², Lawrence Ng², Paris Moaf², Helen Branson², Adrienne Davis², Linda Hiraki⁷, Deborah Levy⁸, ashley Danguecan², George Ibrahim⁵ and Andrea Knight³, ¹University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁵The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, ON, Canada 3Institute of Biomedical Engineering, University of Toronto, Brampton, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive difficulties are common in children with childhood-onset SLE (cSLE), but neuropsychiatric lupus (NPSLE) remains challenging to diagnose and treat. To increase understanding of…
Abstract Number: 0638 • ACR Convergence 2022
Identification of New Candidate Drugs for SLE Using a Drug Repurposing Transcriptomic Approach on Blood, Skin and Kidney Samples from 3439 Patients
Maxime DUBOIS¹, Renaud FELTEN¹ and jacques-eric gottenberg², ¹Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Despite improvements in the understanding of the pathogenesis of Systemic Lupus Erythematosus (SLE), very few new treatments have proven their effectiveness. Drug development is…
Abstract Number: 0658 • ACR Convergence 2022
Integrative Analysis of Cell-Specific Human Endogenous Retrovirus Expression and Host Gene Expression Identifies Associations with Clinical SLE Phenotypes
Zachary Cutts¹, Sarah Patterson², Lenka Maliskova¹, Chun Ye², Maria Dall'Era³, Jinoos Yazdany⁴, Lindsey Criswell⁵, Charles Langelier⁶, Marina Sirota⁷ and Cristina M Lanata⁸, ¹University of California, San Francisco, San Francisco, ²University of California, San Francisco, San Francisco, CA, ³University of California, Division of Rheumatology, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵National Human Genome Research Institute, NIH, Bethesda, MD, ⁶UCSF, San Francisco, ⁷UCSF, SF, ⁸NIH/NHGRI, Washington, DC
Background/Purpose: Human endogenous retroviruses (HERVs) and long interspersed nuclear elements (LINEs) make up 5-8% and 21% of the human genome, respectively. Their expression may contribute…
Abstract Number: 0746 • ACR Convergence 2022
Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial
Ho SO¹, Evelyn Chow², Isaac Cheng¹, Xerox Lau², Tena Li¹, Cheuk Chun Szeto² and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: During the pandemic, vulnerable patients such as those with lupus nephritis (LN) faced the difficult choice between COVID-19 infection risk during a clinic visit…
Abstract Number: 0962 • ACR Convergence 2022
Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm
Megan Clowse¹, Jim Oates², Katie Kirchoff², April Barnado³, Saira Sheikh⁴, Leslie Crofford³ and Amanda Eudy⁵, ¹Duke University, Durham, NC, ²Medical University of South Carolina, Charleston, SC, ³Vanderbilt University Medical Center, Nashville, TN, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Duke University, Raleigh, NC
Background/Purpose: Disparities in pregnancy outcomes among women with SLE remain understudied, with few available racially-diverse datasets. We previously validated algorithms to identify pregnancies in women…
Abstract Number: 0983 • ACR Convergence 2022
Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Jake Altier, Fedelis Mutiso, Paul Nietert, Sheldon Litwin and Jim Oates, Medical University of South Carolina, Charleston, SC
Background/Purpose: Initially used as an antimalarial, hydroxychloroquine (HCQ) is standard of care treatment for systemic lupus erythematosus (SLE) and is used as monotherapy or adjunct…
Abstract Number: 1000 • ACR Convergence 2022
Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study
J. Michelle Kahlenberg¹, Iñaki Sanz², Chun Wu³, Sarah Hu³, Jin Hyang Kim³, Shalabh Singhal³ and Ian M. Catlett³, ¹University of Michigan, Ann Arbor, MI, ²Emory University, Atlanta, GA, ³Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) mediates signaling of key cytokines (eg, Type 1 IFNs, IL-23, and IL-12) involved in lupus pathogenesis. Deucravacitinib (DEUC) has a…
Abstract Number: 1192 • ACR Convergence 2022
Celiac Disease in Patients with Systemic Lupus Erythematosus: An Analysis of Nationwide Inpatient Sample
Jiayi Zheng¹, Ruoning Ni², Guangchen Zou³, Yuhao Zeng⁴, Naeem ijaz¹ and Yani Zhang⁵, ¹The Wright Center for Graduate Medical Education, Scranton, PA, ²Ascension Saint Agnes Hospital, Iowa City, IA, ³Danbury Hospital, Danbury, CT, ⁴Cleveland Clinic Akron General, Akron, OH, ⁵MedStar Union Memorial Hospital, Baltimore, MD
Background/Purpose: Celiac disease is an autoimmune disease characterized by the immunologic reaction to gluten by lymphocytes. Although recent studies suggest an association between celiac disease…
Abstract Number: 1365 • ACR Convergence 2022
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
Ivone Kim, Debra Ryan, Carmen Cheng and Cindy Kortepeter, Food and Drug Administration, Silver Spring, MD
Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…
Abstract Number: 1445 • ACR Convergence 2022
Gastrointestinal Manifestations in Systemic Lupus Erythematosus Are Associated with High Disease Activity and Mortality: A Nationwide Cohort Study from India
Pankti Mehta¹, Akansha Srivastava², Amita Aggarwal², Liza Rajasekhar³, Vineetha Shobha⁴, Chengappa Kavadichanda⁵, ASHISH JACOB MATHEW⁶, Parasar Ghosh⁷, Bidyut Das⁸, Avinash Jain⁹, Ranjan Gupta¹⁰ and Manish Rathi¹¹, ¹King George's Medical University, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴St. John’s Medical College Hospital, Bangalore, India, ⁵JIPMER, Pondicherry, Puducherry, India, ⁶Christian Medical College, Vellore, Vellore, India, ⁷Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁸SCB medical college, Cuttack, India, ⁹SMS Medical College, Lucknow, India, ¹⁰All India Institute of Medical Sciences, New Delhi, India, ¹¹PGIMER Chandigarh, Chandigarh, India
Background/Purpose: Gastrointestinal (GI) manifestations of Systemic Lupus Erythematosus (SLE) although rare are often severe. These are difficult to directly attribute to SLE as they can…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].